In vivo and in silico characterization of apocynin in reducing organ oxidative stress: A pharmacokinetic and pharmacodynamic study.
Acetophenones
/ pharmacokinetics
Aging
/ drug effects
Animals
Antioxidants
/ pharmacokinetics
Blood-Brain Barrier
/ metabolism
Computer Simulation
Diet, High-Fat
Disease Models, Animal
Half-Life
Male
Mice
Mice, Inbred C57BL
Obesity
/ drug therapy
Oxidative Stress
/ drug effects
Reactive Oxygen Species
/ metabolism
Tissue Distribution
NADPH oxidase
PKPD
apocynin
in vivo
obesity
reactive oxygen species
Journal
Pharmacology research & perspectives
ISSN: 2052-1707
Titre abrégé: Pharmacol Res Perspect
Pays: United States
ID NLM: 101626369
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
06
04
2020
revised:
10
07
2020
accepted:
11
07
2020
entrez:
8
8
2020
pubmed:
8
8
2020
medline:
4
6
2021
Statut:
ppublish
Résumé
Apocynin has been widely used in vivo as a Nox2-contaninig nicotinamide adenine dinucleotide phosphate oxidase inhibitor. However, its time-dependent tissue distribution and inhibition on organ reactive oxygen species (ROS) production remained unclear. In this study, we examined apocynin pharmacokinetics and pharmacodynamics (PKPD) after intravenous (iv) injection (bolus, 5 mg/kg) of mice (CD1, 12-week). Apocynin was detected using a HPLC coupled to a linear ion-trap tandem mass spectrometer. Apocynin peak concentrations were detected in plasma at 1 minute (5494 ± 400 ng/mL) (t
Identifiants
pubmed: 32761799
doi: 10.1002/prp2.635
pmc: PMC7406636
doi:
Substances chimiques
Acetophenones
0
Antioxidants
0
Reactive Oxygen Species
0
acetovanillone
B6J7B9UDTR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00635Informations de copyright
© 2020 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.
Références
Hypertension. 2008 Feb;51(2):211-7
pubmed: 18086956
Oxid Med Cell Longev. 2016;2016:7409196
pubmed: 26788250
J Mol Graph Model. 2010 Jun;28(8):899-903
pubmed: 20427217
Proc Natl Acad Sci U S A. 2018 Jun 5;115(23):5839-5848
pubmed: 29802228
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Mar 15;985:180-8
pubmed: 25682338
J Biopharm Stat. 2008;18(6):1084-102
pubmed: 18991109
Br J Pharmacol. 2013 Nov;170(5):1064-77
pubmed: 23957783
AAPS J. 2016 Jan;18(1):47-63
pubmed: 26338231
PLoS One. 2013 Jul 30;8(7):e70189
pubmed: 23936162
Arch Biochem Biophys. 2015 Jun 15;576:39-48
pubmed: 25558793
J Cereb Blood Flow Metab. 2007 Dec;27(12):1908-18
pubmed: 17429347
Front Pharmacol. 2019 Sep 03;10:951
pubmed: 31551769
Br J Clin Pharmacol. 2014 Sep;78(3):441-53
pubmed: 25279404
J Vet Pharmacol Ther. 2016 Jun;39(3):213-23
pubmed: 26592724
Free Radic Biol Med. 2010 Jul 1;49(1):22-30
pubmed: 20347034
Endothelium. 2002;9(3):191-203
pubmed: 12380644
Biomed Res Int. 2014;2014:298020
pubmed: 25140304
J Clin Invest. 2019 Jul 22;129(8):3374-3386
pubmed: 31329158
Photochem Photobiol Sci. 2019 May 15;18(5):1056-1063
pubmed: 30608096
J Comput Aided Mol Des. 2011 Dec;25(12):1095-106
pubmed: 22109848
Mol Cell Biochem. 2018 Aug;445(1-2):79-88
pubmed: 29256115
Physiol Rev. 2007 Jan;87(1):245-313
pubmed: 17237347
Biomed Pharmacother. 2017 Aug;92:421-428
pubmed: 28558355
Int J Mol Sci. 2018 Oct 09;19(10):
pubmed: 30304850
Sci Rep. 2020 Jan 31;10(1):1582
pubmed: 32005915
PLoS One. 2020 Apr 16;15(4):e0231472
pubmed: 32298299
Molecules. 2013 Mar 01;18(3):2821-39
pubmed: 23455672
Mediators Inflamm. 2008;2008:106507
pubmed: 19096513
PLoS One. 2014 Oct 17;9(10):e110708
pubmed: 25329652
Stat Methods Med Res. 2017 Feb;26(1):21-42
pubmed: 24919830